|
イイヅカ ジユンペイ
Iidzuka Jiyunpei
飯塚 淳平 所属 医学部 医学科（東京女子医科大学病院） 職種 准教授 |
|
| 論文種別 | 原著 |
| 言語種別 | 英語 |
| 査読の有無 | 査読あり |
| 表題 | Predictive role of γ‑glutamyltransferase in patients receiving nivolumab therapy for metastatic renal cell carcinoma. |
| 掲載誌名 | 正式名：International Journal of Clinical Oncology 略 称：Int J Clin Oncol ISSNコード：13419625 |
| 掲載区分 | 国外 |
| 巻・号・頁 | 26(3),pp.552-561 |
| 著者・共著者 | ISHIYAMA Yudai†, KONDO Tsunenori,* TACHIBANA Hidekazu, ISHIHARA Hiroki, FUKUDA Hironori, YOSHIDA Kazuhiko, TAKAGI Toshio, IIZUKA Junpei, TANABE Kazunari |
| 発行年月 | 2021/03 |
| 概要 | INTRODUCTION:γ-Glutamyltransferase is reportedly associated with survival in local and metastatic renal cell carcinoma patients; however, its predictive role among patients treated with immune-checkpoint inhibitors are unknown. This study aimed to investigate the role of γ-glutamyltransferase as a predictive marker among metastatic renal cell carcinoma patients undergoing nivolumab therapy.METHODS:We retrospectively evaluated 69 nivolumab-treated metastatic renal cell carcinoma patients upon failure of one or more systematic therapies. Serum γ-glutamyltransferase levels were determined at baseline and 2 months after nivolumab treatment initiation. Patients were classified as high (≥ 49 U/L) and low (< 49 mg/dL) from baseline GGT levels and the outcomes were compared between the two groups. Furthermore, increased (after/baseline ≥ 2) and non-increased (after/baseline < 2) groups were compared. Progression-free survival and overall survival were evaluated after nivolumab initiation.RESULTS:Overall survival was significantly shorter in the high baseline γ-glutamyltransferase group (20.3%) than in the low group (79.7%) (median 2.33 vs not reached [months], p = 0.0051). Progression-free survival and the overall survival were significantly shorter in the increased than in the non-increased group (24.6% and 75.4%, respectively) (median PFS: 4.43 vs 7.23 [months], p = 0.0373/OS: 24.00 vs not reached, p = 0.0467). On multivariate analyses, high baseline γ-glutamyltransferase was an independent factor for overall survival (p = 0.0345) and increased γ-glutamyltransferase was an independent factor for progression-free survival (p = 0.0276) and overall survival (p = 0.0160).CONCLUSIONS:High baseline γ-glutamyltransferase and its early increase are associated with a poor prognosis in metastatic renal cell carcinoma patients receiving nivolumab. Serum γ-glutamyltransferase levels may help predict treatment outcomes. |
| DOI | 10.1007/s10147-020-01819-2 |
| PMID | 33135126 |